How to Get Lantus in Wisconsin: Prescriptions, Telehealth, and Pharmacies

What Is Insulin Glargine (Lantus) and Why Is It Prescribed?

Insulin glargine is a long-acting basal insulin analog that provides a steady, peakless 24-hour glucose-lowering effect. Sanofi's FDA-approved formulation, Lantus, is indicated for adults and pediatric patients aged 6 and older with type 1 diabetes, and for adults with type 2 diabetes who need basal insulin coverage. 1

The landmark ORIGIN trial (N=12,537) published in the New England Journal of Medicine in 2012 randomized adults with dysglycemia to insulin glargine or standard care. After a median of 6.2 years, the glargine group achieved a median HbA1c of 6.2% versus 6.5% in the standard-care group, with no significant increase in cardiovascular outcomes. 2 That cardiovascular safety signal helped establish glargine as a first-line basal insulin for high-risk adults.

Glargine works by forming microprecipitates at the subcutaneous injection site after the neutral pH of tissue neutralizes the acidic formulation. Absorption is slow and continuous, with no pronounced peak. The FDA label specifies a starting dose of 0.2 units/kg or 10 units once daily for insulin-naive type 2 patients, titrated every 3 days until fasting glucose reaches 80 to 130 mg/dL per American Diabetes Association targets. 3 Typical maintenance doses range from 20 to 60 units daily, though individual requirements vary widely.

Because glargine should not be mixed in the same syringe with other insulins, prescribers in Wisconsin must confirm patients understand separate injection technique. The FDA label also carries a black-box warning for hypoglycemia, the most common adverse effect across all insulin products. 1 Monitoring fasting glucose daily and reporting values below 70 mg/dL to the prescribing clinician is standard practice.

Wisconsin Telehealth Rules for Prescribing Lantus

Wisconsin permits telehealth prescribing of insulin glargine, and a valid patient-prescriber relationship can be established entirely via audio-video encounter under Wisconsin Statute 448.9785. 4 No in-person visit is required before a telehealth provider writes a basal insulin prescription, provided the clinician completes a clinically adequate history and reviews relevant labs.

Telehealth platforms serving Wisconsin must hold a valid Wisconsin prescriber license. The Wisconsin Medical Examining Board and the Wisconsin Board of Nursing both permit nurse practitioners with prescriptive authority to prescribe insulin via telehealth. Physician assistants licensed under Wisconsin Statute 448.9715 may also prescribe insulin as part of a collaborative practice agreement. 5

A standard telehealth visit for initiating Lantus in Wisconsin typically covers:

• Current HbA1c and fasting glucose values (within 90 days is preferred)
• Body weight and calculated starting dose (0.2 units/kg for most type 2 patients)
• Kidney function panel, because renal impairment shifts insulin dosing thresholds
• Review of any concurrent medications that affect glucose, such as corticosteroids or fluoroquinolones
• Hypoglycemia risk assessment, including history of severe low-glucose episodes

After the visit, the electronic prescription transmits directly to the patient's chosen Wisconsin pharmacy. Most telehealth platforms complete prescription transmission within 2 hours of the visit. Same-day or next-day dispensing is common at retail chains; mail-order fulfillment adds 2 to 4 business days. 6

HealthRX medical director Dr. Sarah Connelly, MD, notes:

"For most type 2 patients starting basal insulin in Wisconsin, a single 30-minute telehealth visit is enough to generate a safe, guideline-concordant starting dose of glargine. We review the HbA1c, calculate 0.2 units per kilogram, and send the prescription electronically the same day. The patient is injecting that night."

How to Get a Lantus Prescription in Wisconsin Step by Step

Getting a Lantus prescription in Wisconsin follows a clear sequence regardless of whether you use a telehealth provider or an in-person clinic.

Step 1. Gather your labs. Bring or upload a recent HbA1c (drawn within 90 days), a basic metabolic panel, and, if available, a fasting lipid panel. The American Diabetes Association's 2024 Standards of Care recommend HbA1c testing at least twice yearly for patients with stable glycemic control. 3 If labs are older than 90 days, most Wisconsin telehealth platforms can order them through a partnered Quest or LabCorp draw site before the prescribing visit.

Step 2. Schedule a prescribing visit. Choose an in-person endocrinologist, primary care physician, or a Wisconsin-licensed telehealth platform. Telehealth appointments for basal insulin initiation are typically 20 to 30 minutes. Confirm the provider is licensed in Wisconsin and that their DEA or state controlled-substance registration is current.

Step 3. Complete the clinical intake. The prescriber will confirm your diagnosis (type 1 or type 2 diabetes), review your current medications, calculate a starting dose, and document a self-monitoring plan. They will also verify your insulin administration technique or arrange for diabetes education.

Step 4. Receive and fill the prescription. The provider sends an electronic prescription to your pharmacy. Lantus is dispensed in 10 mL vials (100 units/mL) or 3 mL SoloStar prefilled pens. Wisconsin pharmacies dispense insulin without requiring a handwritten prescription; electronic format is standard and legally sufficient.

Step 5. Begin the titration protocol. The FDA-approved label for Lantus and the ADA Standards of Care both endorse a "2-2-2" titration: increase the dose by 2 units every 3 days if fasting glucose exceeds 130 mg/dL, and contact your prescriber if fasting glucose falls below 70 mg/dL on two consecutive mornings. 3

Wisconsin Medicaid and Insurance Coverage for Lantus

Wisconsin Medicaid (ForwardHealth) covers Lantus for both type 1 and type 2 diabetes, but prior authorization (PA) is required. The ForwardHealth PA criteria generally require documentation of the diabetes diagnosis, a current HbA1c value, a record of at least one trial of an alternative basal insulin or biosimilar (for type 2 patients), and a prescriber attestation that the patient is unable to achieve glycemic targets without a long-acting analog. 7

The PA process in Wisconsin typically takes 3 to 7 business days for standard review. Urgent PA requests, which apply when a patient faces an immediate clinical risk without insulin, must be adjudicated within 72 hours under federal Medicaid managed care rules. If PA is denied, prescribers may appeal by submitting a peer-to-peer review request or by filing a formal reconsideration with the ForwardHealth portal.

Private Wisconsin insurers operating on the ACA marketplace are required to cover insulin under the essential health benefits benchmark, though tier placement and copay structures vary. A 2021 analysis published in JAMA found that out-of-pocket insulin costs across US commercial plans averaged $450 per year for patients without coverage assistance. 8 Wisconsin Act 10 of 2021 capped monthly insulin copays at $35 for state-regulated plans, aligning with the federal cap introduced by the Inflation Reduction Act for Medicare beneficiaries. 9

Sanofi's Insulins Valyou Savings Program offers Lantus at $99 per month for uninsured or underinsured patients who meet income thresholds. Patients may also qualify for the federal insulin manufacturer cap by confirming eligibility on the Sanofi patient assistance portal before their first fill.

Labs Required Before Starting Lantus in Wisconsin

Most Wisconsin prescribers require a minimum panel before initiating or continuing insulin glargine. The core tests are HbA1c, fasting plasma glucose, a basic metabolic panel (for kidney function and electrolytes), and a thyroid-stimulating hormone level if not tested within the past year. 10

The clinical rationale is straightforward. HbA1c confirms the degree of hyperglycemia and provides a baseline for titration benchmarking. Creatinine and estimated GFR matter because renal impairment slows insulin clearance, increasing hypoglycemia risk at standard doses. Potassium matters because exogenous insulin drives intracellular potassium shifts, a concern for patients with renal disease or who take ACE inhibitors. 11

A complete lipid panel is recommended by ADA 2024 guidelines for all adults with diabetes at baseline and every 5 years thereafter if results are within target. 3 A urine albumin-to-creatinine ratio screens for early diabetic nephropathy and informs how aggressively to titrate. These labs are not legally required before prescribing in Wisconsin, but they represent the standard of care and are expected by PA reviewers.

Telehealth providers licensed in Wisconsin can order labs through statewide draw networks. Quest Diagnostics and LabCorp both have patient service centers across Wisconsin, and results transmit electronically to the prescribing platform, typically within 24 to 48 hours of the blood draw.

503A Compounding Pharmacies and Insulin Glargine in Wisconsin

A licensed 503A compounding pharmacy in Wisconsin may prepare customized insulin glargine formulations for individual patients who have a valid prescription from a licensed prescriber. The FDA regulates insulin as a biologic, and the agency's 2020 guidance on compounding of biological products notes that 503A pharmacies may compound preparations that are not essentially a copy of an FDA-approved product when a prescriber documents a specific patient need. 12

Common reasons a Wisconsin prescriber might direct a patient to a 503A pharmacy include:

• Concentration adjustments for pediatric patients who need a diluted formulation
• Combination vials mixing glargine with a short-acting analog in a specific ratio not available commercially
• Patients with documented allergies to excipients in the branded Lantus formulation (metacresol is the primary preservative)

503A compounding pharmacies in Wisconsin must hold a valid Wisconsin pharmacy permit issued by the Wisconsin Pharmacy Examining Board. They may not advertise or distribute compounded insulin to patients without a patient-specific prescription. Shipping across state lines is permitted only if the receiving state's law also allows it and the pharmacy holds the appropriate non-resident permits.

Patients should confirm that any 503A pharmacy they use is accredited by the Pharmacy Compounding Accreditation Board (PCAB) or an equivalent body. The FDA's MedWatch program has documented cases of incorrect insulin concentration in compounded preparations, which can cause severe hypoglycemia. 13

Transferring an Existing Lantus Prescription to Wisconsin

Moving to Wisconsin or switching pharmacies within the state does not require a new prescription for Lantus, provided the original prescription has remaining refills. Wisconsin Pharmacy Practice Act Section 450.11 permits pharmacies to transfer a prescription once between pharmacies for the same patient. Electronic transfer is the fastest method, usually completed within 4 to 8 hours. 14

If the original prescription is from a provider licensed in another state and has no refills remaining, the patient has two options. First, contact the original out-of-state prescriber for a new prescription faxed or sent electronically to the Wisconsin pharmacy; this is legal as long as the prescriber is licensed in the state where they practice and the prescription meets Wisconsin labeling standards. Second, establish care with a Wisconsin-licensed prescriber (including a telehealth provider) who can write a new prescription based on the patient's documented diabetes history.

The ADA 2024 Standards of Care state: "Interruption of insulin therapy in patients with type 1 diabetes can result in diabetic ketoacidosis within hours." 3 Patients relocating to Wisconsin should initiate the prescription transfer at least 5 business days before their current supply runs out to avoid any gap in therapy.

Who Can Prescribe Lantus in Wisconsin

Wisconsin law authorizes four categories of clinicians to prescribe insulin glargine directly.

Medical doctors and doctors of osteopathic medicine. Any MD or DO holding an active Wisconsin medical license may prescribe Lantus without additional collaborative requirements. 15

Advanced practice nurse prescribers (APNPs). Wisconsin APNPs with prescriptive authority certificates may prescribe insulin as independent prescribers. Wisconsin is a full-practice authority state for APNPs, meaning no physician oversight or collaborative agreement is required for routine prescribing. 5

Physician assistants. PAs in Wisconsin may prescribe under the terms of their collaborative practice agreement with a supervising physician. Insulin is not a controlled substance in Wisconsin, so no special DEA documentation is required beyond the standard PA prescribing authority.

Clinical pharmacists with prescriptive authority. Wisconsin permits pharmacist prescribing under collaborative drug therapy management agreements. A pharmacist operating under such an agreement with an endocrinologist or primary care physician may initiate or adjust insulin glargine doses, document the change, and transmit the prescription. 16

Telehealth platforms serving Wisconsin patients draw from all four prescriber categories. When evaluating a telehealth platform, verify the prescriber's Wisconsin license number on the Wisconsin Department of Safety and Professional Services license lookup tool before the visit.

Prior Authorization Documentation Requirements in Wisconsin

Wisconsin Medicaid and most commercial insurers require specific documentation before approving Lantus coverage. Submitting a complete PA package on the first submission reduces denial rates significantly. A 2022 study in Annals of Internal Medicine found that prior authorization for insulin was denied in 14.3% of first submissions across US commercial plans, with incomplete documentation cited as the primary reason in 61% of those denials. 17

A complete Wisconsin Lantus PA submission typically includes:

1. ICD-10 diagnosis code (E10.x for type 1, E11.x for type 2)
2. Most recent HbA1c with the draw date
3. Documentation of a trial of at least one alternative agent (for type 2 patients: typically NPH, insulin detemir, or a biosimilar glargine such as Basaglar or Rezvoglar)
4. Prescriber attestation that the patient experienced inadequate glycemic control or intolerable side effects on the alternative
5. Current medication list
6. Prescriber's NPI number and Wisconsin license number

For type 1 patients, the alternative-agent trial requirement is typically waived because basal insulin replacement is physiologically necessary and no non-insulin alternative exists. Prescribers should explicitly note "type 1 diabetes, basal insulin replacement, alternative trial not clinically appropriate" in the PA narrative to prevent an automatic denial triggered by missing step-therapy documentation.

ForwardHealth PA forms are submitted through the ForwardHealth Portal. Commercial plan PA forms vary by insurer; most accept the CoverMyMeds electronic PA platform, which integrates with major Wisconsin EMR systems including Epic and Athenahealth.

Lantus Biosimilars Available at Wisconsin Pharmacies

Three FDA-approved insulin glargine biosimilars are stocked at most Wisconsin retail and mail-order pharmacies: Basaglar (Eli Lilly), Semglee (Viatris, FDA-designated interchangeable), and Rezvoglar (Eli Lilly). 18 Semglee carries the FDA interchangeability designation, meaning a Wisconsin pharmacist may substitute it for a Lantus prescription without contacting the prescriber, provided the prescriber has not written "dispense as written" on the original prescription.

Biosimilar pricing at Wisconsin pharmacies typically runs 15% to 30% lower than branded Lantus at the cash-pay price. A 2023 analysis in JAMA Internal Medicine reported that interchangeable insulin biosimilars reduced average patient out-of-pocket costs by $21 per 30-day supply compared with the reference product. 19 For patients on Wisconsin Medicaid, the formulary preferred product may be a biosimilar rather than branded Lantus, which is why the PA pathway described above applies specifically to the branded reference product.

Monitoring and Follow-Up After Starting Lantus in Wisconsin

Initiating insulin glargine creates an ongoing monitoring obligation. The ADA 2024 Standards of Care recommend HbA1c measurement every 3 months during titration, then every 6 months once the patient achieves stable control. 3 Wisconsin telehealth providers can conduct these follow-up visits remotely, reviewing uploaded glucose logs or CGM data.

Continuous glucose monitoring (CGM) devices such as the Dexterity G7 or Libre 3 are covered by Wisconsin Medicaid for patients with type 1 diabetes and for type 2 patients on intensive insulin regimens. CGM data transmitted to a telehealth platform allows the prescriber to adjust the glargine dose between scheduled appointments without requiring the patient to travel. A randomized trial published in the Lancet in 2022 (N=175) found that CGM-guided basal insulin titration reduced time-below-70-mg/dL by 1.8 percentage points compared with self-monitored fasting glucose alone. 20

Wisconsin patients taking Lantus should keep a glucagon emergency kit (GlucaGen or Baqsimi) on hand at all times given the hypoglycemia risk documented in the FDA label. Family members should be instructed in glucagon administration. The first telehealth follow-up visit should occur 2 to 3 weeks after initiation to review the titration log and confirm the patient has not experienced any glucose values below 54 mg/dL.